Autolus Therapeutics Closes $100M ADS Offering

Ticker: AUTL · Form: 8-K · Filed: Mar 14, 2024 · CIK: 1730463

Autolus Therapeutics PLC 8-K Filing Summary
FieldDetail
CompanyAutolus Therapeutics PLC (AUTL)
Form Type8-K
Filed DateMar 14, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.000042
Sentimentbullish

Sentiment: bullish

Topics: financing, public-offering, cell-therapy

Related Tickers: AUTL

TL;DR

Autolus Therapeutics just raised $100M from an ADS offering to fund their cell therapy pipeline.

AI Summary

On March 14, 2024, Autolus Therapeutics plc announced the closing of its previously announced underwritten public offering of American Depositary Shares (ADSs), raising gross proceeds of approximately $100 million before deducting underwriting discounts and commissions and other offering expenses. The offering involved 10,000,000 ADSs at a public offering price of $10.00 per ADS.

Why It Matters

This capital raise provides Autolus Therapeutics with significant funding to advance its pipeline of cell therapies, potentially accelerating their development and market entry.

Risk Assessment

Risk Level: medium — While the capital raise is positive, the success of Autolus Therapeutics is still dependent on the clinical and regulatory success of its novel cell therapies.

Key Numbers

  • $100.0M — Gross Proceeds (Raised from the public offering of ADSs.)
  • 10.0M — ADSs Offered (Number of American Depositary Shares sold in the offering.)
  • $10.00 — Price per ADS (The public offering price for each ADS.)

Key Players & Entities

  • Autolus Therapeutics plc (company) — Registrant
  • March 14, 2024 (date) — Date of Report
  • $100 million (dollar_amount) — Gross proceeds from offering
  • 10,000,000 (dollar_amount) — Number of ADSs offered
  • $10.00 (dollar_amount) — Public offering price per ADS

FAQ

What was the total amount of gross proceeds raised by Autolus Therapeutics in this offering?

Autolus Therapeutics raised approximately $100 million in gross proceeds before deducting underwriting discounts and commissions and other offering expenses.

How many American Depositary Shares (ADSs) were offered?

The offering involved 10,000,000 ADSs.

What was the public offering price per ADS?

The public offering price per ADS was $10.00.

When did Autolus Therapeutics announce the closing of this offering?

The closing of the offering was announced on March 14, 2024.

What is the primary use of the funds raised from this offering?

The funds raised are intended to advance Autolus Therapeutics' pipeline of cell therapies.

Filing Stats: 842 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-03-14 12:32:35

Key Financial Figures

  • $0.000042 — nting one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Selec

Filing Documents

02 Results of Operations and Financial Conditions

Item 2.02 Results of Operations and Financial Conditions. On March 14, 2024, Autolus Therapeutics plc (the " Company ") issued a press release announcing its recent business highlights and financial results for year ended December 31, 2023. The press release also includes information regarding the Company's previously announced conference call and webcast to be held at 8:30 am EDT/12:30 pm GMT on March 14, 2024 to discuss the results. A copy of the press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. In connection with its conference call on March 14, 2024 to discuss its results for the year ended December 31, 2023, the Company will utilize an updated corporate presentation, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.2 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On March 14, 2024, the Company also announced that Dr. Edgar Braendle, the Company's Chief Development Officer, has tendered his resignation. Dr. Braendle will serve in a consulting capacity to ensure a smooth transition.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits d) Exhibits Exhibit No. Description of Exhibit 99.1 Press release dated March 14, 2024 99.2 Corporate Presentation dated March 2024 104 Cover Page Interactive Date File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTOLUS THERAPEUTICS PLC Dated: March 14, 2024 By: /s/Christian Itin, Ph.D. Name: Christian Itin, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.